Meme Kanseri

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.

Wang W, Sun Y, Li J, et al. Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021. BMC Cancer. 2025 Jun 6;25(1):1015. doi: 10.1186/s12885-025-14416-1.

US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024 Jun 11;331(22):1918-1930. doi: 10.1001/jama.2024.5534. Erratum in: JAMA. 2024 Sep 30. doi: 10.1001/jama.2024.19851.

Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012 Nov 17;380(9855):1778-86. doi: 10.1016/S0140-6736(12)61611-0.

Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin. 2014 May-Jun;64(3):186-94. doi: 10.3322/caac.21225.

American Cancer Society. Breast Cancer Facts & Figures 2023–2024. Atlanta: American Cancer Society; 2023.

World Cancer Research Fund/AICR. Diet, Nutrition, Physical Activity and Breast Cancer. Continuous Update Project Expert Report; 2018.

Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.

Hu C, Hart SN, Gnanaolivu R, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021 Feb 4;384(5):440-451. doi: 10.1056/NEJMoa2005936.

Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012 Nov;13(11):1141-51. doi: 10.1016/S1470-2045(12)70425-4.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Night Shift Work. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 2020;124.

Rodgers KM, Udesky JO, Rudel RA, et al. Environmental chemicals and breast cancer: An updated review of epidemiological literature informed by biological mechanisms. Environ Res. 2018 Jan;160:152-182. doi: 10.1016/j.envres.2017.08.045.

Oeffinger KC, Fontham ET, Etzioni R, et al.; American Cancer Society. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614. doi: 10.1001/jama.2015.12783. Erratum in: JAMA. 2016 Apr 5;315(13):1406. doi: 10.1001/jama.2016.3404.

Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Aug 1;30(8):1194-1220. doi: 10.1093/annonc/mdz173. Erratum in: Ann Oncol. 2019 Oct 1;30(10):1674. doi: 10.1093/annonc/mdz189. Erratum in: Ann Oncol. 2021 Feb;32(2):284. doi: 10.1016/j.annonc.2020.08.2158.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. Version 1.2025. Plymouth Meeting, PA: NCCN; 2025.

D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA. ACR BI-RADS® Atlas: Breast Imaging Reporting and Data System. 5th ed. Reston, VA: American College of Radiology; 2013.

Mann RM, Cho N, Moy L. Breast MRI: State of the Art. Radiology. 2019 Sep;292(3):520-536. doi: 10.1148/radiol.2019182947.

WHO Classification of Tumours Editorial Board. Breast Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.

Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54. doi: 10.1093/jnci/94.20.1546.

King TA, Muhsen S, Patil S, et al. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. J Clin Oncol. 2015 Nov 20;33(33):3945-52. doi: 10.1200/JCO.2015.61.4743.

Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. 2010 Apr;120(2):293-308. doi: 10.1007/s10549-010-0746-x.

Chen AC, Paulino AC, Schwartz MR, et al. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis. Clin Breast Cancer. 2013 Apr;13(2):133-9. doi: 10.1016/j.clbc.2012.10.001.

Reddy TP, Rosato RR, Li X, Moulder S, et al. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020 Nov 4;22(1):121. doi: 10.1186/s13058-020-01353-z.

Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52. doi: 10.1038/35021093.

Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep;24(9):2206-23. doi: 10.1093/annonc/mdt303.

André F, Ciruelos E, Rubovszky G, et al.; SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.

Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822.

Swain SM, Baselga J, Kim SB, et al.; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.

Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4. Erratum in: N Engl J Med. 2017 Oct 26;377(17):1700. doi: 10.1056/NEJMx170012.

Schmid P, Cortes J, Pusztai L, et al.; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.

Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.

Sparano JA, Gray RJ, Makower DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710.

Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–729. doi:10.1056/NEJMoa1602253.

Moran MS, Schnitt SJ, Giuliano AE, et al.; Society of Surgical Oncology; American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014 May 10;32(14):1507-15. doi: 10.1200/JCO.2013.53.3935.

Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis (ACOSOG Z0011). JAMA. 2011;305(6):569–575. doi: 10.1001/jama.2011.90.

Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9.

Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160.

von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE). N Engl J Med. 2019;380:617–628. doi:10.1056/NEJMoa1814017.

Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer (OLYMPIA). N Engl J Med. 2021;384:2394–2405. doi:10.1056/NEJMoa2105215.

Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for high-risk early breast cancer (monarchE). N Engl J Med. 2020;383:2095–2106. doi:10.1056/NEJMoa2009225.

Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5.

Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488.

Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer (PALOMA-2). N Engl J Med. 2016;375:1925–1936. doi: 10.1056/NEJMoa1607303.

Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18. Erratum in: J Clin Oncol. 2023 Aug 10;41(23):3962. doi: 10.1200/JCO.23.01239.

Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPATRA). N Engl J Med. 2015;372:724–734. doi: 10.1056/NEJMoa1413513.

Modi S, Saura C, Yamashita T, et al.; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510.

Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer (IMpassion130). N Engl J Med. 2018;379:2108–2121. doi: 10.1056/NEJMoa1809615.

Robson M, Goessl C, Domchek S. Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. N Engl J Med. 2017 Nov 2;377(18):1792-3. doi: 10.1056/NEJMc1711644.

Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early breast cancer (MINDACT). N Engl J Med. 2016;375:717–729. doi: 10.1056/NEJMoa1602253.